Cargando…

HIV–1 resistance to dolutegravir: update and new insights

Integrase strand transfer inhibitors (INSTIs) are the latest class of potent anti-HIV drugs. Currently, three INSTIs have been approved by the US Food and Drug Administration: raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG). Resistance mutations to RAL and EVG emerge rapidly, and signif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wainberg, Mark A, Han, Ying–Shan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mediscript Ltd 2015
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946665/ https://www.ncbi.nlm.nih.gov/pubmed/27482391

Ejemplares similares

Will drug resistance against dolutegravir in initial therapy ever occur?
por: Wainberg, Mark A., et al.
Publicado: (2015)

Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
por: Mesplède, Thibault, et al.
Publicado: (2014)

The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration
por: Mesplède, Thibault, et al.
Publicado: (2017)

Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy
por: Wainberg, Mark A, et al.
Publicado: (2015)

Erratum for Mesplède et al., “The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration”
por: Mesplède, Thibault, et al.
Publicado: (2018)

The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound
por: Wainberg, Mark, et al.
Publicado: (2014)

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
por: Mesplède, Thibault, et al.
Publicado: (2013)

Dolutegravir/rilpivirine for the treatment of HIV-1 infection
por: Dowers, Ellen, et al.
Publicado: (2018)

The role of dolutegravir in the management of HIV infection
por: Miller, Misty M, et al.
Publicado: (2015)

Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
por: Zamora, Francis J, et al.
Publicado: (2019)

The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance
por: Wainberg, Mark A.
Publicado: (2012)

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS
por: Taha, Huda, et al.
Publicado: (2015)

Dolutegravir Resistance in Malawi’s National HIV Treatment Program
por: van Oosterhout, Joep J, et al.
Publicado: (2022)

First case report of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with tenofovir/lamivudine/dolutegravir use in mothers
por: Francois, Kesner, et al.
Publicado: (2023)

Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection
por: Boffito, Marta, et al.
Publicado: (2020)

Dolutegravir Interactions with HIV-1 Integrase-DNA: Structural Rationale for Drug Resistance and Dissociation Kinetics
por: DeAnda, Felix, et al.
Publicado: (2013)

Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV
por: Kandel, Christopher E, et al.
Publicado: (2015)

Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review
por: Tao, Kaiming, et al.
Publicado: (2023)

A systematic review of the genetic mechanisms of dolutegravir resistance
por: Rhee, Soo-Yon, et al.
Publicado: (2019)

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence
por: Mesplède, Thibault, et al.
Publicado: (2015)

Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs
por: Wainberg, Mark A., et al.
Publicado: (2010)

Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV
por: Dow, Dorothy E., et al.
Publicado: (2014)

Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? A case report
por: Mulindwa, Frank, et al.
Publicado: (2023)

Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV
por: Chapola, John C., et al.
Publicado: (2023)

Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
por: Mulindwa, Frank, et al.
Publicado: (2023)

First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens
por: Fokam, Joseph, et al.
Publicado: (2020)

Stable HIV‐1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study
por: Sculier, D, et al.
Publicado: (2018)

sHIV-1 drug resistance in people on dolutegravir-based ART: Collaborative analysis of cohort studies
por: Loosli, Tom, et al.
Publicado: (2023)

In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2
por: Smith, Robert A, et al.
Publicado: (2015)

HIV drug resistance against strand transfer integrase inhibitors
por: Anstett, Kaitlin, et al.
Publicado: (2017)

Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment
por: Weller, Stephen, et al.
Publicado: (2013)

Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV
por: Saborido-Alconchel, Abraham, et al.
Publicado: (2023)

The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs
por: Wainberg, Mark A., et al.
Publicado: (2012)

HIV-1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence: a case report
por: van Kampen, Jeroen J.A., et al.
Publicado: (2022)

Switch to dolutegravir is well tolerated in Thais with HIV infection
por: Goh, Orlanda Q, et al.
Publicado: (2019)

Combination dolutegravir–abacavir–lamivudine in the management of HIV/AIDS: clinical utility and patient considerations
por: Cruciani, Mario, et al.
Publicado: (2015)

What if HIV were unable to develop resistance against a new therapeutic agent?
por: Wainberg, Mark A, et al.
Publicado: (2013)

Cellular and molecular mechanisms involved in the establishment of HIV-1 latency
por: Donahue, Daniel A, et al.
Publicado: (2013)

Dolutegravir for second-line treatment: Programmatic implications of new evidence
por: Zhao, Ying, et al.
Publicado: (2022)

New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy
por: Carganico, Andreas, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9rv272oas1qkqsqibu71imejsj